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We tested the ability of the thymidine ahalog 3'-azido-3'-deoxythymidine (BWA509U) to inhibit the
replication of the retrovirus avian leukosis virus. Inhibition was measured with two different assays: (i)
inhibition of a single round of virus replication and (ii) inhibition of virus spread through a cell culture. With
both assays, we detected inhibition of virus growth, although inhibition of a single round of virus replication
required a 40-fold higher drug concentration than did inhibition of virus spread. We also detected variations
in the concentrations of drug needed to inhibit virus replication in different cell types. Higher concentrations
of drug were needed to inhibit virus replication in chicken embryo fibroblasts than in the continuous quail cell
line QT6. Viral DNA synthesis in infected cells was shown to be inhibited in the presence of the drug. The
triphosphate form of the analog acted as a competitive inhibitor of purified viral reverse transcriptase, with a
Ki of 0.09 + 0.003 ,iM, and was incorporated as a chain terminator during reverse transcription of the natural
viral RNA substrate in vitro.
Retroviruses are widely distributed among vertebrates.
These viruses share a common life cycle that includes the
reverse transcription of virion RNA into double-stranded
DNA (23). A virus-encoded DNA polymerase (reverse tran-
scriptase) present in the virion is responsible for the synthe-
sis of the double-stranded DNA product (1, 21), a process
that takes place in the cytoplasm of the infected cell (22).
The use of a biochemically distinct polymerase and the
cytoplasmic localization set viral DNA synthesis apart from
the synthesis of cellular chrotnosomal DNA.
Retrovirus polymerases do not have an associated 3' exo-
nuclease activity and therefore are incapable of repairing
misincorporated bases (3). This observation suggests that
retrovirus polymerases may be more sensitive to inhibition
by chain-terminating nucleotide analogs than are polymer-
ases that can repair misincorporated bases. Recently, the
thymidine analog 3'-azido-3'-deoxythymidine was shown to
be a potent inhibitor of human immunodeficiency virus and
other mammalian retroviruses (13, 16). For human immuno-
deficiency virus, both virus replication and virus-induced
cell killing were inhibited by the analog. This inhibition was
obtained at a concentration of azidothymidine that did not
inhibit cell growth. We have extended these studies by
examining the inhibitory effect of azidothymidine on the
replication of avian leukosis virus (ALV). Azidothymidine
was shown to be a potent inhibitor of viral DNA synthesis in
infected cells and, in its triphosphate form, to inhibit purified
viral reverse transcriptase with both synthetic and native
template primers. We also observed differences in cell
sensitivity to azidothymidine. At concentrations that greatly
inhibited virus replication, the growth rate of QT6 cells (14),
a quail cell line, was not affected. In contrast, the growth of
chicken embryo fibroblasts (CEF) was much more sensitive
to the toxic effects of the drug.
* Corresponding author.
MATERIALS AND METHODS
Cells and viruses. Fertile chicken eggs (C/O, virus nega-
tive) were obtained from H and N Farms, Redmond, Wash.
CEF and QT6 cells (14) were maintained as described
previously (15).
Virus stocks were obtained following Polybrene-mediated
transfection of CEF with infectious plasmid clones of viral
DNA (11). Avian neo retrovirus (ANV) was obtained from
pANV-A. The construction of pANV-A will be described
elsewhere (J. Olsen, W. Osheroff, and R. Swanstrom, manu-
script in preparation). This plasmid contains the neomycin
resistance (neo) gene and simian virus 40 promoter cloned
downstream of the viral en' gene. The resulting plasmid
contains the replicative genes of the Schmidt-Ruppin A
strain of Rous sarcoma virus derived from the SRA-2 DNA
clone (5), with the v-src gene being replaced by the neo gene.
Expression of the neo gene in animal cells confers resistance
to cell killing by G418 (19). ALV was obtained from pALV-
Cla. The construction of pALV-Cla will be described else-
where (Olsen et al., in preparation). This plasmid contains
the replicative genes of the Schmidt-Ruppin A strain of Rous
sarcoma virus and lacks all v-src sequences.
The infectivity ofALV was titrated by placing dilutions of
virus-containing medium on fresh QT6 cells and subse-
quently assaying for the presence of reverse transcriptase
activity as described below. The infectious titer (in infec-
tious units per milliliter) was determined from the dilution
endpoint 30 days after infection.
Selection for G418-resistant colonies. On the day prior to
infection, QT6 cells (5.0 x 105) were seeded in 60-mm tissue
culture plates in medium containing various concentrations
of azidothymidine. Twenty-four hours later, the medium was
removed and replaced with medium containing ANV (4 x
102 CFU/ml). After 2 h at 37°C, the virus was removed and
replaced with medium containing 225 ,ug of G418 (GIBCO
Laboratories, Grand Island, N.Y.) per ml. The medium was
changed every 2 to 3 days. Azidothymidine was present in
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the medium throughout. The number of G418-resistant col-
onies was determined after 10 to 12 days.
Enzyme assays. Reverse transcriptase assays were used to
monitor viral infection and were performed as described
previously (15). For the kinetics study (see Fig. 4). the
reaction volumes were increased to 150 tl aind contained
either filtered culture medium from infected cells (0.45-km-
pore filters) or 0.1 U of purified avian myeloblastosis viirus
reverse transcriptase (Life Sciences. Inc.. St. Petersburg.
Fla.).
The incorporation of [3H]TMP into DNA was assayed by
the DEAE filter-binding technique (12) and liquid scintilla-
tion spectrophotometry. Kinetic constants were determined
by fitting the data to a hyperbola by using the method of
Wilkinson (25) and the computer program of Cleland (4).
Enzyme inhibition was analyzed by the method of Spector
and Hajian (20).
The levels of deoxythymidine- and azidothymidine-phos-
phorylating activities in cell extracts were measured as
described previously (6). Products were trapped on DEAE
paper disks.
Viral DNA synthesis in vitro. Viral genomic 70S RNA was
isolated from the Prague C strain of Rous sarcoma virus as
described previously (15). Synthesis of viral DNA in vitro
was carried out in 10-iLl reaction mixtures containing 50 mM
Tris hydrochloride (pH 8.0), 8 mM MgCI2. 40 mM NaCI. 2
mM dithiothreitol, 50 [kg of 70S RNA per ml. 50 F.M dATP.
50 F.M dCTP, 50 p.M dGTP, 50 ,uM TTP, 650 nM [e-32P]
dTTP (800 Ci/mmol; New England Nuclear Corp.. Boston.
Mass.), 100 ,ug of actinomycin D (Sigma Chemical Co.. St.
Louis, Mo.) per ml, and 16 U of avian myeloblastosis virus
reverse transcriptase. When needed. dideoxyribonucleoside
triphosphates were added at the following concentrations:
ddATP, 44 p-M: ddCTP, 20 FkM; ddGTP. 10 FiM: and ddTTP.
40 F.M. The reaction mixtures were incubated at 370C for 30
min. Each reaction was terminated by the addition of a "-[l
solution of 0.1 M EDTA and 1.5 N NaOH, and the viral
RNA was allowed to hydrolyze for 18 h at 22°C. The solution
was neutralized, and the DNA products were concentrated
by ethanol precipitation and fractionated by electrophoresis
through a 12% acrylamide sequencing gel (17).
Analysis of unintegrated viral DNA. Unintegrated viral
DNA was isolated from whole cells by the method of Hirt (8)
as described previously (15). except that the DNA was not
extracted with acid-phenol. Unintegrated DNA was fraction-
ated by electrophoresis in 1.0% agarose (SeaKem LE: FMC
Corp., Marine Colloids Div., Rockland. Maine). The DNA
in the gel was nicked by exposure to ethidium bromide and
UV light, transferred to nitrocellulose paper (BA85: Sch-
leicher & Schuell, Inc., Keene, N.H.). and hybridized at
42°C for 24 h in 50% formamide-10% dextran sulfate as
described previously (2). The radioactive probe was pre-
pared by nick translation (12) of pANV-A to a specific
activity of 1.5 x 108 dpm/p.g with P`-32P]dTTP (600 Ci/mmol:
New England Nuclear) as the radioactive precursor. The
concentration of the radioactive probe in the hybridization
solution was 10 ng/ml. Hybridization was detected by
autoradiography with Kodak X-Omat AR film (Eastman
Kodak Co., Rochester, N.Y.). For quantitation of the
amount of hybridization, radioactive bands were excised
from the nitrocellulose filter by using the exposed autoradio-
gram as a template and counted in Omnifluor (New Englaind
Nuclear). It was found that under the above-described
hybridization conditions, the amount of hybridized DNA
probe was proportional to the amount of DNA loaded on the
gel over the concentration range of DNAs obtained from the
Hirt extr-aicts (data not shown). We and others (15) have
tound that circular DNA is relatively easy to detect in QT6
cells. In various experiments, circular DNA represented 50
to >90%'( of the total unintegrated viral DNA detected.
High-pressure liquid chromatography analysis. Neutralized
perchloi-ic acid extracts of cells treated for 24 h with 50 p.M
I H]Iazidothyrlidine were analyzed by high-pressure liquid
chromatography as described previously (6). Azidothymi-
dine nucleotides were separated by elution with a linear
gradient of 0.015 to 1 M KH2PO4 (pH 3.5) developed over
110 min at a flow rate of 0.5 ml/min. Unlabeled nucleotides
were analyzed in a similar manner.
RESULTS
Inhibition of ANV replication in quail cells by azidothy-
midine. We constructed a replication-competent avian retro-
virus (ANV) that carries and expresses the tweo gene from
Tn5 (Olsen et al.. in preparation). The ANV genome was
constructed by using a modified form of the ALV genome
(10). Since tweo provides a marker for dominant selection
against cell killing by the compound G418 (19), cell transfor-
mation to G418 resistance after virus infection provides a
quantitative measure of a single round of virus replication.
Clonal cell lines that grow in the presence of G418 have a
single copy of the ANV genome, indicating that the resistant
colonies arise as the result of infection by a single virus
particle (data not shown). We used this assay to determine if
azidothymidine could affect the ability of ANV to transform
the continuous quail cell line QT6 (14) to G418 resistance.
Increasing the amount of azidothymidine in the culture
medium decreased virus replication, as measured by the
decreaise in G418-resistant colonies (Fig. 1). The amount of
azidothymidine required to inhibit colony formation 70%
was approximately 40 p.M. The amount required to inhibit
colony formation 90% was 75 F.M.
Lack of inhibition of QT6 cell growth by aziodothymidine at
concentrations that inhibit virus replication. To determine the
effects of azidothymidine on QT6 cells, we studied parame-
ters of cell growth. In the first experiment, we examined the
effect of azidothymidine on the plating efficiency of QT6
cells previously infected with ANV and selected for G418
resistance. In this experiment, 103 ANV-transformed QT6
cells were seeded into 60-mm dishes containing medium with
various concentrations of azidothymidine. These cells had
not previously been exposed to the drug. Twelve days later,
the number of colonies on duplicate plates was determined
(Fig. 1). Concentrations of azidothymidine up to 80 pLM had
no effect on the efficiency of colony formation (Fig. 1);
however, at azidothymidine concentrations greater than 120
F.M both the colony formation (Fig. 1) and the number of
cells per colony (data not shown) significantly declined.
Similar results were obtained for uninfected cells (data not
shown).
In the second experiment, we examined the effect of
azidothymidine on the growth rate of QT6 cells. In this
experiment, 5 x 104 QT6 cells were seeded into wells of
tissue culture plates (2 cm2). After 3.5 h, the medium was
removed and replaced with medium containing azidothymi-
dine. At various times, the cells were removed by trypsin
treatment and counted. Figure 1 shows the results obtained
from counting cells 4 days after seeding. At this time, cells
without drug were rapidly growing. At 80 p.M azido-
thymidine. by which virus infection was inhibited more than
90%. there was no decrease in cell growth. At 200 F.M
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FIG. 1. Effect of azidothymidine (N3dThd) on the replication of ANV and on the growth of QT6 cells. Solid circles represent colony
formation following infection of QT6 cells by ANV. QT6 cells (5.0 x 105) were infected and selected for G418 resistance as described in
Materials and Methods. Azidothymidine was added to the cells 24 h prior to infection. Each point is the average of duplicate measurements.
The 100% value in the absence of azidothymidine corresponds to 347 colonies. Open circles represent colony formation of ANV-infected QT6
cells plated at 103 cells per 60-mm dish. Each point is the average of duplicate measurements. The 100% value corresponds to 150 colonies.
Open triangles represent the number of QT6 cells present after 4 days of culturing in the presence of azidothymidine. The 100% value is 3.8
x 105 cells.
azidothymidine, there was a slight (12%) decrease in cell
growth. At higher concentrations (500 FIM), the drug was
cytotoxic. These data suggest that azidothymidine concen-
trations up to 80 ,uM can inhibit the replication of ANV
without affecting the ability of QT6 cells either to plate at a
low density or to grow at a normal rate.
Effect of azidothymidine on virus spread. The effect of
azidothymidine on virus spread was tested with another
assay. In this experiment, the ALV parent ofANV was used
to infect QT6 cells in the presence of different concentrations
of the thymidine analog. Virus replication was monitored by
noting the appearance of reverse transcriptase-containing
virus particles in the culture medium. A low level of virus
appeared in the control culture 2 days after infection, and the
cultures were monitored for another 2 weeks. After 5 days of
infection, virus in the medium increased linearly. The ap-
proximate biological titer of virus at day 14 in the absence of
drug was 105 infectious units per ml (data not shown). The
increase in virus from days 5 to 14 was inhibited 70% in the
presence of 1 ,uM azidothymidine (Fig. 2). The level of
inhibition was 85% at 3 FLM and 95% at 10 FM. No virus was
detected at higher concentrations of azidothymidine (30, 80,
and 200 p.M).
We next tested the effect of azidothymidine on the repli-
cation of ALV in CEF. Again, the course of infection was
monitored by noting the appearance of virus-associated
reverse transcriptase activity in the medium. The amount of
virus produced by cultures of CEF grown in the presence of
different concentrations of azidothymidine is shown in Fig.
2. Virus production was inhibited 40% at 1 F.M azidothymi-
dine and 80% at 10 p.M azidothymidine. Overall, the amount
of virus produced at different concentrations of azido-
thymidine was approximately twice that produced in QT6
cells. However, in contrast to QT6 cells, the inhibitory effect
on the growth ofCEF was pronounced. Over a 3-day period,
cell growth was inhibited 50% at 5 F.M azidothymidine and
60% at 10 pLM azidothymidine (Fig. 2).
Inhibition by azidothymidine of viral DNA synthesis in
infected cells. The anticipated target of azidothymidine is the
viral DNA polymerase reverse transcriptase. To test this
hypothesis, we examined viral DNA synthesis in infected
cells. QT6 cells that had been preincubated with various
concentrations of azidothymidine for 24 h were infected with
ALV. At 24 h after infection, unintegrated DNA was isolated
by the method of Hirt (8), and the presence of viral DNA was
detected by agarose gel electrophoresis and Southern blot
analysis (Fig. 3A). In this experiment, form I viral DNA was
more prominent than form III viral DNA. There was no
detectable inhibition of viral DNA at an azidothymidine
concentration of 1 F.M (Fig. 3B). Approximately 65% inhi-
bition was apparent at 30 ,uM azidothymidine. At 80 ,uM
azidothymidine, the amount of viral DNA was estimated to
be reduced 90%, and at 200 ,uM azidothymidine, viral DNA
was barely detectable above the uninfected control. These
results show that with increasing concentrations of azido-
thymidine there was a decrease in the amount of viral DNA
synthesized in infected cells. Also, the level of inhibition of
viral DNA at each concentration of the analog closely
paralleled the level of inhibition of a single round of virus
replication, as measured by the G418 resistance assay (Fig.
1).
Effect of azidothymidine on virus release in productively
infected cells. To determine the effect of azidothymidine on
the release of virus from productively infected cells, we
passaged QT6 cells fully infected with ALV in medium
containing 30 p.M azidothymidine and maintained them for
J. VIROL.
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FIG. 2. Effect of azidothymidine (N3dThd) on the spread of ALV through cultures of QT6 cells and CEF. QT6 cells were seeded in
medium containing various concentrations of azidothymidine and infected 24 h later with ALV at a multiplicity of infection of 10-2 infectious
units per cell. At various times after infection, the medium was assayed for reverse transcriptase activity. The 11-day values were replotted
as a function of azidothymidine concentration (inset). Also shown in the inset are data for a similar experiment with CEF, and included are
the results of experiments measuring the effect of azidothymidine on the growth of CEF and QT6 cells.
30 days. Virus production was monitored by measuring the
reverse transcriptase activity in the culture medium. In the
culture that was exposed to azidothymidine, there was only
a slight (10 to 20%) decrease in reverse transcriptase re-
leased into the medium over the course of the experiment
(data not shown).
The infectivity of the virus produced in the presence of
azidothymidine was also tested. In this experiment, QT6
cells were infected with 4 x 102 CFU ofANV in the presence
of 30 ,uM azidothymidine. The resulting G418-resistant col-
onies were pooled. Azidothymidine was maintained in the
medium continuously. The virus produced by the pooled
G418-resistant colonies was found to have the same colony-
forming ability, when normalized to reverse transcriptase
activity, as the parental virus stock (data not shown). From
these experiments, we conclude that azidothymidine has
only a slight effect on the release of virus particles from
productively infected cells and has no effect on the infectiv-
ity of the virus produced.
Inhibition of reverse transcriptase in vitro by azidothymi-
dine triphosphate. To test directly the hypothesis that the
triphosphate of azidothymidine (N3dThdTP) inhibits viral
DNA synthesis, we measured the ability of N3dThdTP to
inhibit the incorporation of dTMP by the viral reverse
transcriptase by using the synthetic template primer
poly(rA) oligo(dT)12 18. We used purified reverse transcrip-
tase from a closely related virus, avian myeloblastosis virus,
and also virus-containing medium from CEF infected with
ALV as a source of enzyme. This latter source allowed us to
assay the same virus stock that was used in the infectivity
experiments. The results with the purified reverse transcrip-
tase (Fig. 4) show that N3dThdTP competitively inhibited
the incorporation of dTMP catalyzed by reverse transcrip-
tase. The apparent Km for dTTP was 80 + 0.7 ,uM, and the
Ki for N3dThdTP was 0.09 + 0.003 ,uM. These results
indicate that N3dThdTP has a much greater affinity for the
enzyme than does the natural substrate dTTP. Similar re-
sults were obtained in experiments with disrupted virus from
the culture medium as the source of enzyme. In these
experiments we determined an apparent Km of 40 + 7 ,uM for
dTTP and a Ki of 0.07 + 0.014 ,uM for N3dThdTP (data not
shown). These apparent Km values are in close agreement
with values reported previously (9).
Incorporation of N3dThdMP during reverse transcription of
viral RNA. We next investigated the effect of N3dThdTP on
DNA elongation by using purified reverse transcriptase with
viral genomic RNA as the template primer (23). Figure 5
shows an analysis of DNA products synthesized in the
absence and presence of N3dThdTP. As expected, in the
absence of N3dThdTP, the predominant DNA product was
strong-stop DNA, the 101-nucleotide-long transcript that is
initiated on the endogenous tRNATrP primer and extends to
the 5' end of the viral RNA template (23). In the presence of
N3dThdTP, the 101-base DNA transcript was again ob-
served; however, a number of new, shorter DNA products
now appeared. In each case, the new DNA product termi-
nated at a thymidine residue, when compared with the
truncated DNA product obtained from DNA synthesis in the
presence of chain-terminating dideoxyribonucleoside tri-
phosphates (17, 18). These results suggest that N3dThdMP is
incorporated as a thymidine analog during reverse transcrip-
tion of viral RNA and results in DNA chain termination.
Phosphorylation of azidothymidine in avian cells. High-
pressure liquid chromatography analysis of extracts pre-
pared from CEF and QT6 cells following incubation with 50
,uM azidothymidine revealed the presence of mono-, di-, and
triphosphate derivatives of azidothymidine in extracts of
CEF and QT6 cells. In both cell types, the level of
azidothymidine monophosphate was higher than the levels
of azidothymidine diphosphate and azidothymidine triphos-
phate (Table 1). Azidothymidine monophosphate levels in
both cell types were substantially lower than the levels
VOL. 61, 1987 2803




















FIG. 3. Effect of azidothymidine (N3dThd) on ALV DNA syn-
thesis in QT6 cells. (A) QT6 cells were seeded in medium containing
various concentrations of azidothymidine and infected 24 h later
with ALV at a multiplicity of infection of 0.9 infectious units per
cell. Twenty-four hours after infection, unintegrated DNA was
fractionated by the Hirt procedure (8), subjected to electrophoresis
in 1% agarose, and transferred to nitrocellulose paper. Viral DNA
was detected by hybridization with a 32P-labeled viral DNA probe
and autoradiography. The mock-infected culture was grown in
medium without azidothymidine. After autoradiography, regions
corresponding to circular and linear forms of viral DNA were
excised from the nitrocellulose filter, and the amount of radioactiv-
ity was determined by liquid scintillation spectrophotometry. Re-
gions from the lane containing the mock-infected sample served as
background controls. (B) The values of the two DNA forms were
summed and plotted as a function of azidothymidine concentration.
The 100% value corresponds to 629 cpm above the background
level. No hybridizing material was seen in the lower-molecular-
weight range of the gel in panel A (not shown).
detected in human, mouse, or monkey cells (7). However,
the levels of the diphosphate and triphosphate derivatives of
azidothymidine were only about 2- to 10-fold lower than
those detected previously in mammalian cells (7). The levels
of the triphosphate form of azidothymidine in CEF and QT6
cells (0.3 FiM) were equal to or greater than the Ki for the
viral reverse transcriptase.
The level of intracellular TTP in QT6 cells was reduced
when azidothymidine was present in the culture medium.
After treatment of QT6 cells for 24 h with 50 ,uM
0.2 0.4 0.6
1/[TT]
FIG. 4. Inhibition of purified avian myeloblastosis virus reverse
transcriptase by N3dThdTP. The inhibition constant (Ki [slope]) for
N3dThdTP was determined by replotting the slope versus the
N3dThdTP concentration (inset). The units for 1/V are pM-1, and
the units for 1/[TTP] are ,wM-1.
azidothymidine, the intracellular levels ofTTP dropped from
the control level of 190 pmol/106 cells (130 ,uM) to 60
pmol/106 cells (40 jxM).
Phosphorylation of deoxythymidine and azidothymidine by
cell extracts. Cytosol extracts of QT6 cells catalyzed the
phosphorylation of deoxythymidine and azidothymidine at
35 and 20 pmol/min per mg of protein, respectively, at 37°C.
The ratio of these activities for the different substrates (1.7)
was very similar to that observed previously with extracts of
human cells or with purified human thymidine kinase (1.5
and 1.7, respectively). However, the absolute rates of phos-
phorylation were 31- to 37-fold lower with the QT6 cell
extracts than with the human cell extracts (7). These results
suggest that the low level of N3dThdMP seen in QT6 cells is
due, in part, to a low level of thymidine kinase activity.
DISCUSSION
Inhibition of ALV replication by azidothymidine. Retrovi-
rus DNA polymerase is an attractive target for an inhibitor of
virus replication since it is virus encoded and required for
viral DNA synthesis (20). These studies show that the
thymidine analog azidothymidine inhibits the replication of
ALV in infected cells (Fig. 1 and 2) and, in its triphosphate
form, is a potent inhibitor of purified avian myeloblastosis
virus DNA polymerase activity (Fig. 4 and 5). There is a
direct correlation between the level of inhibition of a single
round of virus replication and the reduction of the amount of
viral DNA synthesized in infected cells in the presence of the
drug (Fig. 1 and 3). Since the inhibition of virus replication in
QT6 cells occurs at levels of azidothymidine that do not
affect the growth rate of the cells, it is likely that the action
of the analog is specific for the virus rather than an indirect
effect of cellular toxicity. Our results extend those of previ-
ous studies which showed that azidothymidine can inhibit
human immunodeficiency virus and other mammalian retro-
J. VIROL.

















FIG. 5. Chain termination by N3dThdTP during reverse tran-
scription of viral RNA in vitro. In reactions containing N3dThdTP.
the concentration is indicated at the top of the figure. Reactions
containing ddATP (lane A), ddCTP (lane C), ddGTP (lane G). or
ddTTP (lane T) are also indicated. The DNA sequence on the left
matches the known complementary sequence near the 5' terminus of
the Prague C strain of Rous sarcoma virus RNA (18). Positions of
ambiguity (where bands appear at the same position in all lanes) are
in parentheses. The nucleotide length. in bases from the tRNATrP
primer, is indicated on the right.
viruses (13, 16). The fact that this analog inhibits an avian
retrovirus and mammalian retroviruses whose polymerases
are only distantly related at the sequence level (24) suggests
that azidothymidine will be broadly inhibitory against retro-
viruses.
Assay-dependent inhibition. Our results show that there
can be significant variability in the apparent level of inhibi-
tion depending on the type of assay and the type of cell used
to measure virus growth. Using the same virus and cells in
two different assays, we found a 40-fold difference in the
concentration of azidothymidine needed to inhibit virus
replication 70%. An assay designed to measure inhibition of
a single round of replication was much less sensitive to
inhibition than was an assay designed to measure an increase
in the amount of virus produced by a culture after virus
spread (Fig. 1 and 2). This difference can be understood by
the fact that virus spread is the result of several rounds of
virus replication, each of which can be inhibited. However,
measuring the inhibition of a single round of virus replication
provides a more stringent assessment of the inhibitory effect
of this or any compound.
Variability was also apparent when the results obtained
with two different cell types. QT6 cells and CEF, were
TABLE 1. Anabolism of azidothymidine in CEF and QT6 cells"
Concn (pmol/106 cells) of indicated
Cells derivative of azidothymidine
Monophosphate Diphosphate Triphosphate
CEF 1.4 (0.9) 0.7 (0.5) 0.4 (0.3)
QT6 2.5 (1.7) 0.5 (0.4) 0.4 (0.3)
" CEF and QT6 cells were incubaited with 50 ,uM [3H]azidothymidine
(424.000 dpm/pmol) for 24 h. Neutr-atlized perchloric acid extracts of the
treated cells were analyzed by high-pressure liquid chromatography. Concen-
trations were calculated based on a single-cell volume of 1.5 pl. Cell volume
was determined by platcing 100 p.1 of a cell suspension of known concentration
in a capillary. pelleting the cells, and measuring the column height of the cell
pellet. Values in patrentheses represent micromolar concentrations.
compared (Fig. 2). Virus growth in QT6 cells, as measured
by virus spread, was more sensitive to the analog than was
virus growth in CEF, even though CEF showed much
greater sensitivity to azidothymidine and the sensitivity was
over the same range of concentrations that inhibited virus
replication. Thus, at least some of the inhibition of virus
spread in CEF was probably a result of a toxic effect on the
host cell. The differential sensitivity of CEF and QT6 cells
was not due to different levels of phosphorylated azido-
thymidine present in the cells, since these levels were
approximately the same in each cell type (Table 1). It is not
clear why virus replication was less sensitive to inhibition in
CEF at equivalent levels of drug. One possible explanation
may be in differences in the rate of virus spread through
cultures. If virus spread in CEF is significantly more efficient
than that in QT6 cells, it could obscure differences in the
level of inhibition of DNA synthesis during a single round of
infection. Virus sensitivity to azidothymidine, cellular tox-
icity from the analog, and ease of virus spread may all
contribute to the final level of virus that is produced in a
certain cell type or, potentially, in a certain tissue type.
Phosphorylation of azidothymidine in avian cells and inter-
action of its triphosphate with viral DNA polymerase. Ex-
tracts from QT6 cells catalyzed the phosphorylation of
azidothymidine. The ratio of the rates of phosphorylation of
thymidine and azidothymidine was very similar to that seen
previously with human cells (7); it is likely that cytosolic
thymidine kinase phosphorylates azidothymidine to its
monophosphate in QT6 cells. The low level of thymidine
kinase observed in the QT6 extracts correlates with the
observation (Table 1) that the level of N3dThdMP was much
lower than that seen previously in human cells (7).
At present, the mechanism(s) by which azidothymidine
inhibits retrovirus DNA replication is not completely under-
stood. N3dThdTP could inhibit ALV replication by chain
termination of DNA synthesis (Fig. 5), by competitive
inhibition of reverse transcriptase (Fig. 4), or by a combina-
tion of the two. The fact that a full-length DNA product is
synthesized in infected cells treated with azidothymidine in
the apparent absence of premature termination products
(Fig. 3) suggests that competitive inhibition rather than chain
termination may be the predominant mechanism of inhibi-
tion in infected cells. N3dThdTP must be able to compete
with TTP to act as an inhibitor for the reverse transcriptase.
With a Ki of 0.09 FM (Fig. 4) and an intracellular concen-
tration of 0.3 pLM in the presence of 50 F.M azidothymidine
(Table 1). N3ThdTP should be able to compete favorably
with TTP, which has an apparent K,., of 40 to 80 F.M and an
intracellular concentration of 40 F.M in the presence of 50
p.M azidothymidine. These nucleotide concentrations should
result in 60 to 70% inhibition. This level of inhibition is very
VOL. 61, 1987 2805
2806 OLSEN ET AL.
close to the 65% inhibition of viral DNA synthesized in
infected cells in the presence of 30 ,uM azidothymidine (Fig.
3) and similar to the level of inhibition of a single round of
virus replication at an equivalent drug concentration (Fig. 1).
However, a direct comparison between results obtained in
vitro and in infected cells is difficult to make since we do not
know the Ki of N3dThdTP for reverse transcriptase with its
natural RNA and DNA templates.
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